TauRx Pharmaceuticals has filed a marketing authorisation application (MAA) with the UK Medicines and Healthcare products Regulatory Agency, seeking approval for hydromethylthionine mesylate (HMTM) to treat Alzheimer’s disease (AD). HMTM is intended for treating mild cognitive impairment due to Alzheimer’s disease (MCI-AD) and mild to moderate dementia stages associated with AD. The gold standard of business intelligence.
The UK regulator had previously designated the innovative licensing and access pathway for HMTM. The UK could become the first country to offer this oral treatment on approving HMTM. TauRx’s MAA for the asset is underpinned by comprehensive evidence from the 24-month Phase III LUCIDITY clinical trial and two previous Phase III studies.
These trials consistently demonstrated HMTM’s benefits in slowing cognitive decline, maintaining daily living activities and reducing brain atrophy rates. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Tau aggregation, a key factor in Alzheimer’s, correlates with cognitive decline severity and brain nerve cell damage.
HMTM counters this by selectively inhibiting tau-protein agg.